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Abstract: Invasion, metastasis and resistance to conventional chemotherapeutic agents are 
obstacles to successful treatment of pancreatic cancer, and a better understanding of the 
molecular basis of this malignancy may lead to improved therapeutics. In the present study, 
we  investigated  whether  AKT2  silencing  sensitized  pancreatic  cancer  L3.6pl,  BxPC-3, 
PANC-1 and MIAPaCa-2  cells  to  gemcitabine  via regulating PUMA (p53-upregulated 
modulator of apoptosis) and nuclear factor (NF)-κB signaling pathway.  MTT,  TUNEL, 
EMSA and NF-κB reporter assays were used to detect tumor cell proliferation, apoptosis 
and NF-κB activity. Western blotting was used to detect different protein levels. Xenograft 
of  established  tumors  was  used  to  evaluate  primary  tumor  growth  and  apoptosis  after 
treatment  with  gemcitabine  alone  or  in  combination  with  AKT2  siRNA.  Gemcitabine 
activated AKT2 and NF-κB in MIAPaCa-2 and L3.6pl cells in vitro or in vivo, and in 
PANC-1 cells only in vivo. Gemcitabine only activated NF-κB in BxPC-3 cells in vitro. The 
presence of PUMA was necessary for gemcitabine-induced apoptosis only in BxPC-3 cells 
in vitro. AKT2 inhibition sensitized gemcitabine-induced apoptosis via PUMA upregulation 
in MIAPaCa-2 cells in vitro, and via NF-κB activity inhibition in L3.6pl cells in vitro. In 
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PANC-1 and MIAPaCa-2 cells in vivo, AKT2  inhibition  sensitized  gemcitabine-induced 
apoptosis and growth inhibition via both PUMA upregulation and NF-κB inhibition. We 
suggest that AKT2 inhibition abrogates gemcitabine-induced activation of AKT2 and NF-κB, 
and promotes gemcitabine-induced PUMA upregulation, resulting in chemosensitization of 
pancreatic tumors to gemcitabine, which is probably an important strategy for the treatment 
of pancreatic cancer. 
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1. Introduction 
Pancreatic cancer has the worst survival rate of all cancers. It is more common in elderly than in 
younger persons, and <20% of patients present with localized, potentially curable tumors. A much 
higher percentage of patients present with metastatic disease (40–45%) or locally advanced disease 
(40%),  and  have  median  survival  times  of  3–6  or  8–12  months,  respectively.  The  overall  5-year 
survival rate among patients with pancreatic cancer is <5% [1–3]. The frustrating lack of significant 
clinical  advancements  in  the treatment  of metastatic pancreatic cancer remains  one of  the biggest 
disappointments  in  medical  oncology.  Invasion,  metastasis  and  resistance  to  conventional 
chemotherapeutic  agents  are  obstacles  to  successful  treatment  of  pancreatic  cancer,  and  a  better 
understanding of the molecular basis of this malignancy may lead to improved therapeutics [4–6]. 
AKT  (also  known  as  protein  kinase  B)  is  a  Ser/Thr  kinase  that  belongs  to  the  AGC  family 
(AMP/GMP kinases and protein kinase C) of kinases [7]. The three AKT isoforms: AKT1, AKT2 and 
AKT3 are closely related and consist of a conserved N-terminal pleckstrin homology (PH) domain, a 
central  catalytic domain and a  C-terminal  regulatory  hydrophobic motif (HM) [8]. Recent  reports   
have demonstrated that the phosphatidylinositol-3 kinase (PI3K)/AKT pathway is a potent survival 
signal  that  may  mediate  resistance  to  the  apoptotic  effects  of  chemotherapy  therapy  in  different   
cancer types [9–13]. 
The current standard care for metastatic pancreatic cancer is gemcitabine, however, the success of 
this treatment is poor and overall survival has not improved for several decades. Drug resistance (both 
intrinsic and acquired) is thought to be a major reason for the limited benefit of most pancreatic cancer 
therapies [2]. It has been reported recently that strong expression levels of AKT2 and phosphorylated 
AKT  (pAKT)  are  found  and  p-AKT  expression  is  a  significant  prognostic  indicator  for  pancreatic   
cancer [14]. Many reports suggest that inhibition of AKT activation enhances sensitivity to gemcitabine 
in pancreatic cancer [15–18]. However, the mechanism of AKT activation in pancreatic cancer remains 
unknown. Relatively little is known about the downstream signaling events that regulate sensitivity to 
gemcitabine in pancreatic cancer. 
Nuclear factor (NF)-κB is a ubiquitous transcription factor that is  regulated by a vast array of 
stimuli, including growth factors, inflammatory mediators, cytotoxic agents such as chemotherapeutic 
drugs, oxidative stress, and UV light. NF-κB is a dimer composed of various combinations of the five 
mammalian Rel proteins, namely, p65/RelA, c-Rel, RelB, NF-κB1/p50, and NF-κB2/p52 [19]. The 
most common form of NF-κB is a dimer of p65/relA and p50, and this dimer is often referred to Int. J. Mol. Sci.2012, 13  1188 
 
simply  as  NF-κB.  In  many  human  cancers,  including  pancreatic  cancer,  constitutive  activation  of 
NF-κB has been observed and may be associated with chemotherapy resistance, including gemcitabine, 
and inhibition of NF-κB may be useful for enhancing sensitivity to chemotherapy in cancer therapy [20–23].   
Recent studies have shown that activation of AKT leads to activation of a series of survival factors, 
including NF-κB, arming cancer cells to resist induction of apoptosis [24,25]. The apoptosis induced 
by blocking PI3K/AKT might be ascribed to inhibition of NF-κB activity in pancreatic cancer cell   
lines [18,26]. However, Arlt et al. have reported that basal AKT activity correlates with sensitivity 
towards  gemcitabine  treatment,  and  that  inhibition  of  PI3K/AKT  by  LY294002  alters 
gemcitabine-induced apoptosis, however, it is the constitutive NF-κB activity that confers resistance 
against gemcitabine [22]. Fahy et al. [18,26] have reported recently that the antiapoptotic effect of 
AKT activation in pancreatic cancer cells may involve transcriptional induction of NF-κB and Bcl-2 
proteins  that  confer  resistance  to  apoptosis;  alteration  of  this  balance  allows  sensitization  to  the 
apoptotic effect of chemotherapy. This was similar to the previous reports. However, Pan et al. [21] 
have  reported  that  silencing  p65/relA  induced  apoptosis  and  increased  gemcitabine  killing  of   
all  gemcitabine-sensitive  pancreatic  cancer  cells,  and  no  significant  effects  were  observed  on 
gemcitabine-resistant pancreatic cancer cell lines either in vitro or in vivo. Some studies have recently 
shown that knockdown of AKT enhances gemcitabine chemosensitivity in pancreatic adenocarcinoma 
cells [27]. However, there is no evident change in NF-κB activity when AKT activity decreases in 
PANC-1 cells [18]. We suggested the apoptosis or sensitivity to gemcitabine induced by blocking 
PI3K/AKT  might  be  ascribed  to  inhibition  of  NF-κB  activity  at  least  in  part,  the  other  signaling 
pathway may take part in the downstream signaling events of the AKT activity regulation, NF-κB may 
not be the main mechanisms of apoptosis regulation in some pancreatic cancer cell lines. 
PUMA (p53-upregulated modulator of apoptosis) is a Bcl-2 homology 3 (BH3)-only Bcl-2 family 
member  and  a  critical  mediator  of  p53-dependent  and  -independent  apoptosis  induced  by  a  wide 
variety of stimuli, including genotoxic stress, deregulated oncogene expression, toxins, altered redox 
status, growth factor/cytokine withdrawal, and infection [28,29]. PUMA ablation or inhibition leads to 
apoptosis  deficiency  and  increased  risk  for  cancer  development  and  treatment  resistance,  and 
inhibition of PUMA expression may be useful for curbing excessive cell death associated with tissue 
injury and degenerative diseases [30–36]. Therefore, PUMA is a general sensor of cell death stimuli 
and a promising target for cancer therapy. 
De Frias et al. [35] have recently reported that AKT inhibitors may induce apoptosis of chronic 
lymphocytic leukemia cells irrespective of TP53 status, followed by an increase in PUMA protein 
levels and decrease in MCL-1 protein level. Fraser and colleagues have found that activation of AKT 
inhibits cisplatin-induced upregulation of PUMA, and suppresses cisplatin-induced p53 phosphorylation. 
They have also found that inhibition of AKT increases total and phospho-p53 content and sensitizes 
p53  wild-type,  chemoresistant  cells  to  cisplatin-induced  apoptosis  [36].  Ishihara  et  al.  [37]  have 
reported that PUMA siRNA inhibits the celecoxib-induced activation and translocation of Bax, release 
of cytochrome c into the cytosol and induction of apoptosis, suggesting that PUMA plays an important 
role in celecoxib-induced mitochondrial dysfunction and the resulting apoptosis. Coloff et al. [38] 
have reported that AKT-mediated cell survival is crucial in normal immunity and cancer, through 
AKT-dependent  stimulation  of  glycolysis  to  suppress  PUMA  expression.  Karst  et  al.  [39]  have 
reported  a  negative  relationship  between  expression  of  PUMA  and  pAKT,  and  boosting  PUMA Int. J. Mol. Sci.2012, 13  1189 
 
expression,  combined  with  inhibiting  AKT  phosphorylation  reduces  cell  survival.  PUMA  has 
proapoptotic  effects  and  sensitivity  to  chemotherapy,  thus,  it  is  possible  that  activated  AKT  may 
suppress apoptosis via PUMA downregulation. In the present study, we investigated the hypothesis that 
inhibition  of  activated  AKT  promotes  gemcitabine-induced  apoptosis  and  confers  gemcitabine 
sensitivity in cultured pancreatic cancer cells, in part, by PUMA upregulation.   
In  the  present  study,  we  investigated  the  hypothesis  that  inhibition  of activated  AKT  promotes 
gemcitabine-induced apoptosis  in cultured pancreatic cancer cells, in  part,  by  PUMA  upregulation 
and/or by NF-κB activity inhibition. 
2. Materials and Methods 
2.1. Cell Culture 
Human PANC-1 and MIAPaCa-2 pancreatic cancer cells, which are resistant to gemcitabine [21,24], 
were purchased from the American Type Culture Collection (ATCC). The BxPC-3 cell line, which is 
sensitive to gemcitabine [21], was also purchased from ATCC. PANC-1 and MIAPaCa-2 cells were 
routinely cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (BxPC-3 were cultured in RPMI 
1640)  supplemented  with  10%  fetal  bovine  serum  (FBS)  in  a  37  C  incubator  in  a  humidified 
atmosphere of 5% CO2. Human pancreatic cancer L3.6pl cells, which produce a significantly higher 
incidence of liver metastasis and number of lymph nodes, were obtained from M.D. Zhang [40,41]. All 
the  cells  were  maintained  in  continuous  exponential  growth  by  twice-weekly  passage  in  DMEM 
supplemented with  10%  FBS,  100 U/mL penicillin  and 100 mg/mL streptomycin  in  a humidified 
incubator containing 5% CO2 in air at 37 C. 
2.2. Reagents 
The antibodies used  were  AKT2 and wtp53  (DO-1)  (Santa Cruz  Biotechnology),  Phospho-Akt 
(Ser473), Bcl-2, β-actin (Sigma–Aldrich), Anti-PUMA-α, Anti-NF-κBp65(p65) and caspase-3 (active) 
(Abgent) and PUMA siRNA (h) (Santa Cruz Biotechnology).   
2.3. Construction of Adeno-Associated Virus-Mediated AKT2 siRNA Vector   
AKT2 is amplified in human pancreatic cells, and inhibition of AKT2 expression contributes to the 
pathogenesis and malignant phenotype of this highly aggressive form of human malignancy [42–45]. 
Although  pAKT1  is  overexpressed  in  pancreatic  cancer,  high  pAKT1  expression  is  a  favorable 
prognostic factor in pancreatic cancer [46]. Therefore, we used AKT2 for the present study. The 21-mer 
sense and antisense strands of AKT2 RNA oligonucleotides were designed as described previously [47]. 
AKT2 siRNA duplexes were designed according to AKT2 mRNA sequences obtained from National 
Center for Biotechnology Information database (accession no: NM_001626.3). RNA oligonucleotides 
were synthesized by GeneChem (Shanghai, China) as previously described [48]. The sequence was 
subjected to a Blast search against the human genome sequence to ensure that only the AKT2 gene was 
targeted. Adeno-associated-virus-mediated transfer of AKT2 siRNA or mock siRNA [rAAV2-AKT2 
siRNA or rAAV2-mock siRNA] were generated as described previously [49]. High-titer viruses were 
produced in 293 cells and purified by CsCl2 gradient ultracentrifugation. Int. J. Mol. Sci.2012, 13  1190 
 
2.4. Adenoviral Infection 
Cells were infected with AKT2 siRNA or mock siRNA at 10, 50, 100 and 500 MOI for 48 h. 
Expression  of  various  proteins  was  confirmed  by  western  blotting.  EMSA  was  used  to  detect   
NF-κB activity. 
2.5. Transient Transfection 
Cells or AKT2 siRNA (mock siRNA)-transfected cells were cultured overnight in six-well plates 
and then transfected with 2, 10 or 20 µg PUMA siRNA (and negative control) using Lipofectamine 
Plus (Invitrogen) in 1 mL serum-free medium according to the manufacturer’s instructions. Four hours 
post-transfection, each well was supplemented with 1 mL medium containing 20% FBS. Twenty-four 
hours post-transfection, medium was removed and the cells were harvested or treated with gemcitabine 
for a further 72 h. 
2.6. Drug Treatments 
L3.6pl, BxPC-3, PANC-1 and MIAPaCa-2 cells were plated at a density of 5 ×  10
4 cells/cm
2 on 
six-well plates 18 h before initiation of treatment. At the time of treatment, cell density was >70%. The 
cells  were  treated  with  (1)  1  µM  gemcitabine  (MIAPaCa-2,  BxPC-3  and  PANC-1)  or  0.5  µM 
gemcitabine (L3.6pl) for 72 h; (2) 10, 50 and 100 MOI AKT2 siRNA (mock siRNA) transfection for 
48 h, followed by the same concentration of gemcitabine for 72 h; (3) 0.1, 0.5 or 1 µM  gemcitabine for 
72  h;  (4)  MIAPaCa-2  and  L3.6pl  cells  were  treated  with  100  MOI  AKT2  siRNA  (mock  siRNA) 
transfection for 48 h, followed by 1 µM gemcitabine and 5, 10 or 20 U tumor necrosis factor (TNF)-α 
for 72 h; or (5) MIAPaCa-2 and L3.6pl cells were treated with 100 MOI AKT2 siRNA (mock siRNA) 
transfection for 48 h followed by 2, 10 or 20 µg PUMA siRNA transfection for 24 h, then the cells 
were treated with 1 µM gemcitabine for an additional 72 h.   
2.7. MTT Assay 
Cell  viability  was  examined  by  the  MTT  assay  method.  At  various  times,  20  µL 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/mL in PBS) was 
added to each well and incubated for a further 2 h. Upon termination, the supernatant was aspirated 
and the MTT formazan formed by metabolically viable cells was dissolved in 100 µL isopropanol. The 
plates were mixed for 30 min on a gyratory shaker, and absorbance was measured at 595 nm using a 
plate reader. 
2.8. TUNEL Assay 
The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was 
performed to detect apoptotic cells according to the manufacturer’s instructions. The in vivo TUNEL 
assay was performed as described previously [50]. Stained sections of tumors of each group were 
reviewed,  and the apoptosis  index  (AI) was  determined by TUNEL staining, by counting at  least   
1000 cells in five randomly selected high-power fields (magnification, × 200).   Int. J. Mol. Sci.2012, 13  1191 
 
2.9. Preparation of Nuclear and Cytoplasmic Extracts 
Nuclear and cytoplasmic soluble extracts were prepared from the cells described above in various 
groups in various time point using a rapid version of the method as previously described [51,52]. 
Cytoplasmic extracts were obtained by diluting the supernatant obtained after the first centrifugation 
with three volumes of buffer D [52]. 
2.10. Western Blotting 
Total cellular proteins were isolated and the protein concentration of the sample was determined by 
BioRad  DC  Protein  Assay  (Bio-Rad  Laboratories,  Hercules,  CA,  USA).  NF-κB  p65/relA,  AKT 
phosphorylated  at  Ser473  and  β-actin  were  detected  as  described  previously  [23,27].  For  wtp53 
(DO-1), Bcl-2,phospho-p
21Cip/Waf1, phospho-IκBα, PUMA and caspase-3 analysis, aliquots of 1–10 µg 
of  proteins  were  resolved  by  SDS-PAGE,  transferred  to  membranes,  and  probed  with  the  above 
mentioned primary antibodies. The targeted protein was revealed by enhanced chemiluminescence 
(ECL). The membrane was incubated with an ECL solution (Biological Industries) and exposed to 
ECL  film  (Eastman  Kodak,  Rochester,  NY,  USA)  to  visualize  specifically  labeled  proteins.  The 
resulting exposed films were then analyzed by densitometry. All experiments were performed at least 
three times. 
2.11. NF-κB Activity Assay 
The cells (1 ×  10
5) described above in various groups in various time points were seeded in 60-mm 
dishes and simultaneously transfected with Lenti-NF-κB-luc and Lenti-Ubiquitin-Renilla-Luc (25 µL 
of each viral supernatant/mL medium) mixed with polybrene (4 µg/mL medium) to develop stable 
cells expressing the NF-κB reporter and the renilla luciferase control [27]. Reporter activities were 
measured  using  the  Dual  Luciferase  reporter  assay  system  (Promega)  at  24  h  after  transfection, 
according  to  the  manufacturer’s  instructions.  Reporter  activities  were  normalized  using  Renilla 
luciferase values. 
2.12. Detection of NF-κB Binding Activity by EMSA   
Nuclear protein extracts were prepared as described previously [51–55]. The sequence of the NF-κB 
oligonucleotide  probe  was  5'-AGTTGAGGGACTTTCCCAGGC-3'.  EMSA  was  performed  as 
described previously [51,52]. 
2.13. Tumor Xenografts and Tissue Staining   
All animal experiments were approved by Qingdao Medical College, Qingdao University. Tumor 
xenografts were established by s.c. injection of 5 ×  10
6 L3.6pl, PANC-1 or MIAPaCa-2 cells into both 
flanks of 5–6-week-old female athymic nude mice. When the tumor was 50–100 mm
3, the mice were 
randomized into the following treatment groups (n = 6 each): (1) untreated control; (2) gemcitabine   
(80 mg/kg) twice weekly (i.v. injection); (3) each tumor was injected with rAAV2-AKT2 siRNA or 
rAAV2-mock siRNA at 10
9 pfu in 100 μL PBS. Each treatment was repeated three times (from day 0, Int. J. Mol. Sci.2012, 13  1192 
 
once  every  other  day);  and  (4)  gemcitabine  and  rAAV2-AKT2  siRNA  or  rAAV2-mock  siRNA, 
following the schedule for the individual treatments. Tumor growth was monitored three times weekly 
by calipers to calculate tumor volumes according to the formula (length ×  width
2)/2. TUNEL staining 
on frozen sections was done according to the manufacturer’s instructions. The protein of AKT2, pAkt 
(Ser473), NF-κB, bcl-2, PUMA and β-actin in frozen sections was determined by western blotting. 
Frozen sections were also analyzed by hematoxylin and eosin staining. 
2.14. Statistical Analysis 
All  experiments  were  independently  performed  at  least  three  times.  Unless  otherwise  stated,  a 
representative experiment is displayed. Error bars denote SDs. P values were calculated by Student’s   
t test or ANOVA. Differences were considered to be statistically significant at P < 0.05. 
3. Results 
3.1. Knockdown of AKT2 Reduces NF-κB Activity in Pancreatic Cancer Cell Lines 
Western blotting was used to measure wt-p53, NF-κBp65 and AKT2 (pAKT) (Figure 1A). NF-κB 
activity was measured using the reporter assay and nuclear NF-κB DNA binding was observed by 
EMSA (Figure 1B,C). Dose-dependent inhibition of pAKT and NF-κB activation was found in L3.6pl, 
PANC-1 and MIAPaCa-2 cells treated with AKT2 siRNA, but not in BxPC-3 cells because of their low 
basal AKT2 level (Figure 1A–C). There was no obvious change in wt-p53 expression in the four cell 
lines  (Figure  1A).  Mock  siRNA  (10,  50,  100  or  500  MOI)  did  not  have  any  effect  on  protein 
expression and activity in the four cell lines (data not shown). 
3.2. Differential Response to Chemotherapy in Pancreatic Cancer Cell Lines with Varying Levels of 
AKT2 Inhibition 
Fahy  et  al.  [21,26]  have  reported  that  AKT  inhibition  is  associated  with  gemcitabine 
chemosensitization  in  MIA-PaCa-2  cells  via  inhibition  of  NF-κB  activity.  We  evaluated  whether 
NF-κB activity suppression via AKT2 specific inhibition chemosensitized to gemcitabine in the other 
pancreatic cancer cells. Two gemcitabine-sensitive (L3.6pl and BxPC-3) and two resistant (PANC-1 
and MIA-PaCa-2) cell lines [21] were exposed to a series of concentrations of AKT2 siRNA or mock 
siRNA (10, 50, 100 or 500 MOI) for 48 h to knock down AKT2, followed by 0.5 µmol/L gemcitabine 
for L3.6pl cells and 1 µmol/L for PANC-1, BxPC-3 and MIA PaCa-2 cells for 72 h, as described 
previously [21,54]. MTT analysis was conducted to measure cell viability and proliferation in response 
to gemcitabine treatment in AKT2 siRNA-transfected-L3.6pl, BxPC-3, PANC-1 and MIAPaCa-2 cells 
(Figure 2A). In all the four cell lines, depletion of AKT2 alone did not induce significant proliferation 
inhibition  compared  to  the  controls  (P  >  0.05)  (Figure  2A).  However,  gemcitabine  treatment  in 
AKT2-silenced cells resulted in significant cell proliferation inhibition in L3.6pl cells (P < 0.01) and 
MIA PaCa-2 cells (P < 0.05) compared to cells treated with gemcitabine alone (Figure 2A). Treatment 
with gemcitabine for 72 h led to cell proliferation inhibition that was similar to that with combined 
treatment of BxPC-3 and PANC-1 cells (P > 0.05) (Figure 2A). The same sensitivities were obtained 
when the  effects  of  gemcitabine  (0.5 or 1  µM) combined with  AKT2  inhibition  (MOI  = 100)  on Int. J. Mol. Sci.2012, 13  1193 
 
apoptosis were analyzed using TUNEL assay (Figure 2B), and when the four cells transfected with   
100 MOI rAAV2-AKT2 siRNA were treated with 0.1–1 µM gemcitabine (data not shown). 
Figure 1. Effects of AKT2 inhibition on NF-κB activity. (A) L3.6pl, BxPC-3, PANC-1 and 
MIAPaCa-2 cells were treated with 10, 50, 100 or 500 MOI rAAV2-AKT2 siRNA for 48 h. 
AKT2,  pAKT  (pAKTscr
473),  wt-p53  and  NF-κBp65  levels  were  detected  by  western 
blotting; (B) Nuclear extracts prepared from L3.6pl, BxPC-3, PANC-1 and MIAPaCa-2 
cells after 48 h incubation with 10, 50, 100 and 500 MOI rAAV2-AKT2 siRNA, and were 
assayed by EMSA; (C) NF-κB transcriptional activity was estimated using a reporter assay. 
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Figure  2.  MTT  and  TUNEL  assay  showing  cytotoxic  effect  of  gemcitabine  on  AKT2 
siRNA-transfected pancreatic cancer cell lines. (A) Cell viability assay was performed at 
72 h after treatment with gemcitabine. AKT2 siRNA-transfected L3.6pl and MIA PaCa-2 
cells showed significantly higher susceptibility to gemcitabine compared to gemcitabine 
alone (*  P  < 0.05, ** P  < 0.01).  AKT2 siRNA-transfected  BxPC-3 and PANC-1 cells 
showed similar susceptibility to gemcitabine compared to gemcitabine alone (P > 0.05);   
(B) TUNEL analysis for measuring apoptosis induced by AKT2 inhibition, gemcitabine, 
and  AKT2  inhibition  combined  with  gemcitabine  treatment.  AKT2  siRNA  transfection 
alone failed to induce apoptosis and inhibited proliferation in the four cell lines. In both 
assays,  three  separate  experiments  were  performed  and  data  from  one  representative 
experiment (mean ±  SD of four replicates) are shown. 
 
3.3. Effect of Gemcitabine on Activation of AKT and NF-κB in Pancreatic Cancer Cells 
Following exposure to  apoptotic stimuli,  cells may engage survival  mechanisms  to  subvert the 
induction of cell death. NF-κB and AKT activity is such signaling, which may increase survival and 
protect  cancer  cells  from  chemotherapy  [11–14,20–23].  Colin  et  al.  [15]  have  reported  that 
gemcitabine induces a rapid increase in pSer
473Akt levels over a period of 15 min to 6 h. No significant 
activation of AKT in PANC-1 or AsPC-1 cells was observed following gemcitabine treatment. L3.6pl, 
BxPC-3, PANC-1 and MIAPaCa-2 cells were treated with 1 µM gemcitabine for 24–72. Significant 
activation of AKT2 was shown in MIAPaCa-2 and L3.6pl cells over 48 h, but AKT2 activity began to Int. J. Mol. Sci.2012, 13  1195 
 
decline after 48 h (Figure 3A,B). No significant activation of AKT2 in PANC-1 and BxPC-3 cells   
was  observed  following  gemcitabine  treatment  for  72  h,which  was  consistent  with  the  study  of   
Banerjee et al. [54] (Figure 3A,B). Pan et al. [21] have reported that gemcitabine treatment for 24 h 
does not influence NF-κB activity in pancreatic cancer cells in vitro. However, Amit Verma et al. [53] 
have reported that NF-κB activity was significantly increased by 0.1 µM gemcitabine for 48 h in 
L3.6pl cells. There was significant NF-κB activity in MIAPaCa-2 and L3.6pl cells after 48 h treatment 
with gemcitabine, and after 72 h treatment in BxPC-3 cells (Figure 3A,B) (P < 0.05). No significant 
activation of NF-κB in PANC-1 cells was observed following gemcitabine treatment for 72 h (P > 0.05) 
(Figure 3A,B). Gemcitabine treatment did  not  induce NF-κB and  AKT2 activity in  PANC-1 cells. 
Although NF-κB activity was induced in BxPC-3 cells  after gemcitabine treatment, no significant 
activation of AKT2 was observed. However, significant activation of AKT2 in L3.6pl and MIAPaCa-2 
cells was observed, followed by activation of NF-κB after gemcitabine treatment. To evaluate whether 
activation of NF-κB after gemcitabine treatment was AKT2 dependent, L3.6pl and MIAPaCa-2 cell 
lines were transfected with AKT2 siRNA or mock siRNA (MOI 100) for 48 h, and then the cells were 
treated  with  1  µM  gemcitabine  for  72  h.  As  shown  in  Figure  3C,  NF-κB  activity  was  reduced 
significantly in L3.6pl and MIAPaCa-2 cells after combined treatment. We therefore confirmed that 
gemcitabine-induced activation of NF-κB is AKT2 dependent in L3.6pl and MIAPaCa-2 cells. 
Figure  3.  Western  blotting  and  EMSA  for  AKT2  (pSer473),  pAKT  and  NF-κBp65 
following treatment with gemcitabine and/or AKT2 siRNA. (A) Western blotting for AKT2 
(pSer473), pAKT and NF-κBp65 in four pancreatic cancer cell lines following treatment 
with  gemcitabine  (1  μM)  for  72  h  in  L3.6pl,  MiaPaCa-2,  BxPC-3  and  PANC-1  cells;   
(B) Relative Akt2 (pSer473), pAKT and NF-κBp65 levels are shown (vs. control,* P < 0.05); 
(C) Nuclear extracts prepared from L3.6pl and MIAPaCa-2 cells after 48 h incubation with 
1 μM gemcitabine combined with 100 MOI AKT2 siRNA were assayed by EMSA.   
 Int. J. Mol. Sci.2012, 13  1196 
 
3.4. PUMA Is Required for Gemcitabine-Induced Apoptosis in Pancreatic Cancer Cells 
We first investigated the effect of gemcitabine on p53, PUMA and PUMA-responsive gene product 
cytochrome C and caspase-3 in L3.6pl, MiaPaCa-2, BxPC-3 and PANC-1 cells growing in normal 
media. All these experiments were done three times. The cells exhibited significantly increased p53, 
PUMA, cytochrome C and caspase-3 expression after treatment with gemcitabine in BxPC-3 cells as 
compared with MiaPaCa-2, L3.6pl and PANC-1 cells (Figure 4A). Furthermore, BxPC-3 cells exhibited 
significantly  decreased  PUMA,  cytochrome  C  and  caspase-3  expression  when  gemcitabine-treated 
cells were transfected with PUMA siRNA (20 µg) to knock down PUMA content, and significantly 
decreased  AI  without  affecting  p53  (Figure  4B).  Although  gemcitabine  induced  apoptosis  in 
MiaPaCa-2 and L3.6pl cells, followed by upregulation of p53, PUMA, cytochrome C and caspase-3, 
no significant difference was found compared with the PUMA siRNA-transfected groups (data not 
shown).  The  data  suggest  that  PUMA  is  required  for  gemcitabine-induced  apoptosis  mainly  in 
gemcitabine-sensitive BxPC-3 in vitro. 
Figure 4. Gemcitabine modulates p53 downstream target protein expression and induces 
apoptosis. L3.6pl, MiaPaCa-2, BxPC-3 and PANC-1 cells were treated with gemcitabine 
(0.1, 0.5 and 1 µM) or combination of gemcitabine and PUMA siRNA. Levels of p53, 
PUMA,  cytochrome  C  (cyt.  C)  and  caspase-3  were  determined  by  western  blotting;   
(A) Basal PUMA protein was detectable in PANC-1 cells, but was undetectable in L3.6pl, 
MiaPaCa-2 and BxPC-3 cells. Expression of p53, PUMA, cyt C and caspase-3 proteins was 
significantly increased in the BxPC-3 cell line treated with gemcitabine. There was no 
significant  increase  in  proteins  in  L3.6pl,  MiaPaCa-2  and  PANC-1  cells  treated  with 
gemcitabine; (B) BxPC-3 cells were transfected with PUMA siRNA in the presence or 
absence of 0.1–1 µM gemcitabine. PUMA and  p53-responsive gene product cyt C and 
caspase-3 were significantly decreased, however, p53 was not affected; (C) BxPC-3 cells 
transfected with PUMA siRNA had a significantly decreased AI (* P < 0.05, ** P < 0.01). 
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3.5. Induction of PUMA-Dependent Sensitivity to Gemcitabine by Inhibition of AKT2 Activity, as a 
Mechanism of Apoptosis Promotion in Pancreatic Cancer Cells   
As shown above, inhibition of AKT2 enhanced sensitivity to gemcitabine in MiaPaCa-2 and L3.6pl 
cells. Fahy et al. [18,26] have reported that AKT inhibition is associated with chemosensitization in 
MIA-PaCa-2 pancreatic cancer cells via inhibition of NF-κB activity. We investigated how inhibition 
of AKT2 enhanced sensitivity to gemcitabine, by inducing the PUMA or NF-κB signaling pathway. 
MiaPaCa-2 and L3.6pl cells were treated with 100 MOI AKT2 siRNA or mock siRNA for 48 h, and 
then the transfected cells were exposed to 1 µM gemcitabine for 4 h. TNF-α (5–20 U) was added to the 
cells treated with rAAV2 and gemcitabine for 72 h. TNF-α significantly increased NF-κB activity in 
both cell lines in a concentration-dependent manner (Figure 5A, E). PUMA and PUMA-responsive 
gene product  cytochrome C and active caspase-3 were significantly increased in  MiaPaCa-2 cells 
treated with AKT2 siRNA and gemcitabine (Figure 5C). There was no significant increase in L3.6pl 
cells (Figure 5G). Enhancement of apoptosis induced by combined gemcitabine and AKT2 siRNA was 
not decreased significantly when NF-κB activity was activated and its downstream bcl-2 protein was 
increased in MiaPaCa-2 cells (Figure 5B). However, enhancement of apoptosis induced by combined 
gemcitabine and AKT2 siRNA was decreased significantly when NF-κB activity and its downstream 
bcl-2 protein were increased in L3.6pl cells (Figure 5F). 
To  determine  whether  inhibition  of  AKT2  enhances  sensitivity  to  gemcitabine  via  PUMA 
upregulation,  MiaPaCa-2  cells  treated  with  AKT2  siRNA  and  gemcitabine  were  transfected  with 
PUMA siRNA to knock down PUMA (Figure 5C). Enhancement of apoptosis induced by combined 
gemcitabine and AKT2 siRNA was decreased significantly (Figure 5D). However, apoptosis was not 
decreased significantly when L3.6pl cells treated with AKT2 siRNA and gemcitabine were transfected 
with PUMA siRNA (Figure 5H). 
AKT2/pAKT  expression  was  not  found  in  basal  level  and  gemcitabine-treated  BxPC-3  cells, 
therefore, we could conclude that there was no relationship between AKT2/pAKT expression and 
sensitivity to gemcitabine. Although the AKT2 basal level was high in PANC-1 cells, there was no 
relationship between AKT2/pAKT expression and sensitivity to gemcitabine. 
These results indicate that inhibition of AKT2 enhanced sensitivity to gemcitabine in MiaPaCa-2 
cells via a PUMA-dependent, but not NF-κB pathway. This was contrary to previous studies [18,26]. In 
L3.6pl cells, inhibition of AKT2 enhanced sensitivity to gemcitabine via an NF-κB-dependent, but not 
PUMA  pathway.  In  PANC-1  cells,  resistance  to  gemcitabine  is  not  AKT2  or  NF-κB-dependent. 
However, BxPC-3 cells were sensitized to gemcitabine via an AKT2/pAKT-independent NF-κB and   
PUMA pathway. Int. J. Mol. Sci.2012, 13  1198 
 
Figure 5. In vitro mechanism of action of gemcitabine alone and in combination with 
AKT2 inhibition. (A,E) L3.6pl and MiaPaCa-2 cells were treated with gemcitabine (0.1, 
0.5  or  1  µM),  combination  of  gemcitabine  and  AKT2  siRNA  (100  MOI),  or  TNF-α   
(5–20 U). Western blotting was used to detect NF-κBp65 and Bcl-2; (C,G) L3.6pl and 
MiaPaCa-2  cells  were  treated  with  gemcitabine  (0.1,  0.5  or  1  µM),  combination  of 
gemcitabine and AKT2 siRNA (100 MOI), or PUMA siRNA (20 µg). Western blotting was 
used to detect PUMA and its downstream gene; (B,F,D,H) TUNEL method was used to 




3.6. Effect of Gemcitabine Alone and in Combination with AKT2 siRNA on Primary Tumor Growth   
in Pancreatic Cancer In Vivo 
To determine whether AKT2 confers tumor resistance in vivo, tumor xenografts were established by 
s.c.  injection  of  5  ×   10
6  L3.6pl,  PANC-1,  BxPC-3  or  MIAPaCa-2  cells  into  both  flanks  of 
5–6-week-old female athymic nude mice. When the tumor was 50–100 mm
3, it was injected with 
rAAV2-AKT2  siRNA  or  rAAV2-mock  siRNA  at  10
9  pfu  in  100  μL  PBS,  and  the  treatment  was 
repeated three times (once every other day, from day 0). To avoid potential systemic effects of different 
viruses, rAAV2-AKT2 siRNA and rAAV2-mock siRNA were injected into separate tumors in the same Int. J. Mol. Sci.2012, 13  1199 
 
animals. rAAV2-AKT2 siRNA did not have any effect on tumor growth compared with PBS alone or 
rAAV2-mock siRNA alone after 35 days treatment (data not shown). 
To determine whether gemcitabine can effectively inhibit growth of established tumors  in vivo, 
gemcitabine alone (80 mg/kg), twice weekly (i.v. injection) was used to treat established tumors for   
35 days. In contrast to gemcitabine sensitivity levels in vitro, gemcitabine significantly reduced tumor 
weight in PANC-1 and L3.6pl xenografts (P < 0.05), whereas BxPC-3 and MIAPaCa-2 became drug 
resistant (P > 0.05) (Figure 6A).   
Figure 6. Effect of rAAV2-AKT2 siRNA combined with gemcitabine on tumor growth.  
(A) Tumor weight in mice treated with vehicle control, gemcitabine (gem.; 80 mg/kg twice 
weekly,  i.v.),  rAAV2-AKT2  siRNA  combined  with  gemcitabine,  Columns,  mean  (six 
samples  per  group);  bars,  SD.  All  statistical  tests  were  two  sided  (*  P  <  0.05,   
**  P  <  0.01,  ***  P  >  0.05);  (B)  Growth  curve  of  L3.6pl,  PANC-1,  BxPC-3  and 
MIAPaCa-2 tumors (n = 6 per group) treated with gemcitabine (80 mg/kg twice weekly, 
i.v.) or rAAV2-AKT2 siRNA combined with gemcitabine. Student’s t test versus control 
group; * P < 0.05, ** P < 0.01. 
 
To determine whether knockdown of AKT2 could sensitize to gemcitabine, we treated established 
tumors of PANC-1, BxPC-3, L3.6pl and MIAPaCa-2 with gemcitabine combined with rAAV2-AKT2 
siRNA or rAAV2-mock siRNA. Established MIAPaCa-2 and PANC-1 tumors subjected to combined 
treatment grew much slower and reached less than twice the initial volume, with at least 60% growth 
suppression  compared  with  gemcitabine  alone  (P  <  0.05;  Figure  6A,B).  Combined  treatment 
significantly  reduced  tumor  weight  in  PANC-1  and  MIAPaCa-2  xenografts  compared  with 
gemcitabine alone (Figure 6A) (P < 0.05). In established BxPC-3 and L3.6pl tumors, AAV2-AKT2 
siRNA combined with gemcitabine did not affect tumor growth compared with gemcitabine alone   
(P > 0.05; Figure 6 A,B). Int. J. Mol. Sci.2012, 13  1200 
 
3.7. Effect of Gemcitabine Alone and in Combination with AKT2 siRNA on Primary Tumor Apoptosis 
in Pancreatic Cancer In Vivo   
TUNEL assay revealed many apoptotic cells in the established L3.6pl and PANC-1 tumors treated 
with gemcitabine alone compared with control tumors (P < 0.05) (Figure 7). However, treatment with 
gemcitabine  alone  did  not  increase  the  number  of  apoptotic  cells  in  MIAPaCa-2  and  BxPC-3 
established tumors (Figure 7). In PANC-1 and MIAPaCa-2 established tumors, rAAV2-AKT2 siRNA 
combined  with  gemcitabine  treatment  increased  the  number  of  apoptotic  cells  compared  with 
gemcitabine alone (Figure 7). In the L3.6pl and BxPC-3 established tumors, rAAV2-AKT2 siRNA 
combined with gemcitabine did not affect the number of apoptotic cells compared with gemcitabine 
treatment alone (P > 0.05) (Figure 7). These data show that knockdown of  AKT2 can effectively 
sensitize to gemcitabine treatment and inhibit growth of MIAPaCa-2 and PANC-1 established tumors 
in vivo, at least partially through induction of apoptosis.   
Figure  7.  Effect  of  rAAV2-AKT2  siRNA  in  combination  with  gemcitabine  on  tumor 
growth.  TUNEL analysis  of apoptotic  cells.  Resutls  shown as  mean ±  SEM from  two 
independent experiments. * P < 0.05, ** P< 0.01, *** P > 0.05 by Student’s t test. 
 
3.8. Effect of Gemcitabine Alone and in Combination with AKT2 siRNA on PUMA and NF-κB   
in Pancreatic Cancer In Vivo   
We  measured  the  levels  of  PUMA  and  its  downstream  targets,  NF-κBp65  and  its  downstream 
targets bcl-2, AKT2 and pAKT in established tumors by western blotting. After 6 weeks treatment, 
there was a dramatic increase in the levels of PUMA and its downstream targets in MIAPaCa-2 and 
PANC-1 established tumors treated with rAAV2-AKT2 siRNA combined with gemcitabine, and in 
control  tumors  (Figure  8A,B).  In  PANC-1  established  tumors,  gemcitabine  significantly  increased 
PUMA level and its downstream targets compared with control tumors, which was contrary to the in 
vitro  study  (Figure  4).  However,  in  MIAPaCa-2  established  tumors,  gemcitabine  did  not  increase 
PUMA level, which agreed with the in vitro study (Figure 4). We also observed that gemcitabine 
increased NF-κBp65 level in PANC-1 established tumors, which was contrary to the in vitro study 
(Figure8C).  In MIAPaCa-2 and PANC-1 established tumors, rAAV2-AKT2 siRNA combined with 
gemcitabine  significantly  decreased  NF-κB  expression  and  increased  expression  of  PUMA  and  its Int. J. Mol. Sci.2012, 13  1201 
 
downstream targets compared with control tumors (Figure 8A,B). Pan et al. [21] have reported that 
silencing NF-κB does not sensitize to gemcitabine-induced apoptosis in vivo and in vitro, therefore, we 
suggest that rAAV2-AKT2 siRNA combined with gemcitabine inhibits growth of MIAPaCa-2 and 
PANC-1 established tumors by PUMA upregulation, at least in part. Whether NF-κB downregulation 
plays an important role needs further investigation.   
Figure 8. Western blotting analysis of the effect of rAAV2-AKT2 siRNA in combination 
with gemcitabine treatment on levels of PUMA and its downstream targets, NF-κBp65 and 
its  downstream  targets  bcl-2,  AKT2  and  pAKT  in  established  tumors  after  6  weeks 
treatment. (A,B) In MIAPaCa-2 and PANC-1 established tumors, rAAV2-AKT2 siRNA 
combined  with  gemcitabine  significantly  decreased  NF-κB  expression  and  increased 
expression  of  PUMA  and  its  downstream  targets  compared  with  control  tumors;   
(C) Treatment with rAAV2-AKT2 siRNA combined with gemcitabine did not increase the 
levels of PUMA and its downstream targets compared with gemcitabine treatment alone in 
L3.6pl cells. However, there was a decrease in NF-κB expression in L3.6pl established 
tumors treated with rAAV2-AKT2 siRNA combined with gemcitabine. 
 
L3.6pl  established  tumors  treated  with  gemcitabine  alone  showed  a  significant  increase  in 
expression of nuclear p65 expression and PUMA and its downstream targets compared with control 
tumors,  which  agreed  with  the  in  vitro  study  (Figure  3).  However,  treatment  with  rAAV2-AKT2 
siRNA combined with gemcitabine did not increase the levels of PUMA and its downstream targets 
compared with gemcitabine treatment alone (Figure 8C). We observed a significant decrease in NF-κB 
expression in L3.6pl established tumors treated with rAAV2-AKT2 siRNA combined with gemcitabine 
(Figure  8C).  In  BxPC-3  established  tumors,  gemcitabine  or  rAAV2-AKT2  siRNA  combined  with 
gemcitabine treatment did not affect expression of NF-κB and PUMA (data not shown). 
4. Discussion 
Studies have established AKT as an important regulator of cell proliferation and survival [56,57]. 
Furthermore,  AKT  also  plays  an  important  role  in  cancer  therapy  by  promoting  resistance  to  the Int. J. Mol. Sci.2012, 13  1202 
 
apoptosis-inducing  effects  of  chemotherapy  [56–59].  In  some  pancreatic  cancer  cells,  inhibition   
of  AKT  has  repeatedly  and  consistently  been  shown  to  sensitize  to  the  apoptotic  effect  of 
chemotherapy  [16,18,26].  The  mechanism  by  which  AKT  activation  in  these  cancer  cells  confers 
chemoresistance is not clear. However, in some pancreatic cancer cells, basal AKT activity does not 
correlate  with  sensitivity  towards  gemcitabine  treatment,  nor  does  inhibition  of  PI3K/AKT  by 
LY294002 alter gemcitabine-induced apoptosis [22]. 
Our results demonstrated that inhibition of AKT2 activity itself did not inhibit growth and promote 
apoptosis in PANC-1, L3.6pl, BxPC-3 and MIAPaCa-2 cells in vitro and in vivo. The results of the 
present study also illustrate the variable expression and activity of AKT across a panel of pancreatic 
cancer  cell  lines,  although  basal  level  of  activation  could  not  be  used  to  predict  sensitivity  to 
gemcitabine treatment. Therefore, we investigated the mechanism by which pancreatic cancer cells are 
sensitized or become resistant to gemcitabine treatment. 
In the present  study, the cell lines  L3.6pl and  BxPC-3  were sensitive to  gemcitabine, whereas 
MIAPaCa-2 and PANC-1 cells were resistant in vitro, which is consistent with the recent study by   
Pan et al. [21]. In contrast to gemcitabine sensitivity levels in vitro, the growth of PANC-1 xenografts 
was inhibited by gemcitabine treatment, whereas BxPC-3 cells became resistant, consistent with the 
recent study by Pham et al. [60], which suggests that the tumor microenvironment has an important 
role in determining drug sensitivity. 
The mechanism of L3.6pl and BxPC-3 cell sensitivity to gemcitabine in vitro is somewhat different. 
In  BxPC-3  cells,  gemcitabine  induces  the  direct  targeting  of  p53-dependent  PUMA  upregulation, 
followed by significant cell death and induction of apoptosis. However, inhibition of PUMA activity 
using an siRNA directed at PUMA could reduce chemosensitivity to gemcitabine. We showed that p53 
was required for gemcitabine-induced apoptosis in BxPC-3 cells in vitro, and that this was dependent 
upon  induction  of  PUMA.  In  L3.6pl  cells,  though  sensitive  to  gemcitabine,  no  obvious  PUMA 
upregulation was shown after gemcitabine treatment. The mechanism for this is unknown and could be 
explained by increased translation of other (BH3)-only proteins. Although gemcitabine induces the 
direct targeting of p53-dependent PUMA upregulation in MIAPaCa-2 cells, PUMA was not sufficient 
to induce apoptosis in vitro. In PANC-1 and L3.6pl cells, gemcitabine did not induce changes in the 
PUMA profile in vitro, however, gemcitabine induced an obvious increase in the PUMA profile in 
established  tumors.  Therefore,  we  suggest  that  gemcitabine  sensitizes  tumors  in  vivo  by  inducing 
PUMA  upregulation.  BxPC-3  cells  became  drug  resistant  in  vivo,  opposite  to  its  mechanism  of 
inducing PUMA profile in vitro. These observations may be attributed to the mechanism of PUMA 
upregulation to sensitize gemcitabine in pancreatic cancer. 
PI3K/AKT is a fundamental signaling pathway that mediates several cellular processes, including 
cell  proliferation,  growth,  survival  and  motility  [61–63].  Increased  activation,  deregulation  and 
mutation of the components in the PI3K/AKT pathway have been implicated in driving tumorigenesis 
and conferring resistance to chemotherapy [64,65]. 
Previous studies have shown [18,26] that inhibition of PI3K or AKT decreases the level of the 
antiapoptotic protein Bcl-2 and increases the level of the proapoptotic protein BAX. Furthermore, 
inhibition of AKT decreased the function of NF-κB, which is capable of transcriptional regulation of 
the  Bcl-2  gene  in  MIAPaCa-2  cells.  Inhibition  of  this  pathway  increased  the  apoptotic  effect  of 
chemotherapy. However, we found that inhibition of AKT2 enhanced sensitivity to gemcitabine in Int. J. Mol. Sci.2012, 13  1203 
 
MiaPaCa-2 cells, followed by decreased NF-κB activity in vitro. When NF-κB activity was recovered 
in MiaPaCa-2 cells, enhancement of apoptosis induced by gemcitabine combined with AKT2 siRNA 
was not decreased significantly when NF-κB activity was activated and its downstream bcl-2 protein 
was increased. On the contrary, enhancement of apoptosis induced by gemcitabine combined with 
AKT2  siRNA  was  decreased  significantly  when  PUMA  was  inhibited.  These  results  indicate  that 
inhibition of AKT2 enhances sensitivity to gemcitabine in MiaPaCa-2 cells via a PUMA-dependent, but 
not the NF-κB pathway in vitro. In MIAPaCa-2 established tumors, rAAV2-AKT2 siRNA combined 
with gemcitabine significantly inhibited tumor growth, followed by PUMA upregulation after 5 weeks 
treatment,  contrary  to  the  study  in  vitro.  Pan  et  al. [27]  have  reported  that  silencing  of  p65/relA   
is  effective  alone  and  in  combination  with  gemcitabine  in  gemcitabine-sensitive  but  not 
gemcitabine-resistant  pancreatic  cancer  cells.  In  the  present  study,  although  combined  treatment 
decreased  NF-κB  activity,  we  suggest  that  knockdown  of  AKT2  combined  with  gemcitabine   
inhibits  the  in  vivo  growth  of  MIAPaCa-2  established  tumors  by  PUMA  upregulation,  and  not   
NF-κB downregulation. 
PANC-1 would have been resistant to the tested agent gemcitabine in vitro, although inhibition of 
AKT2 decreased the NF-κB activity and its downstream bcl-2 protein, it did not induce apoptosis. 
Furthermore, gemcitabine did not induce PUMA upregulation. The results indicated that resistance to 
gemcitabine  in  PANC-1 cells  in  vitro was  not  AKT2-, PUMA-  or  NF-κB-dependent.  However,  in 
PANC-1 established tumors, gemcitabine or combined treatment significantly promoted apoptosis and 
inhibited tumor growth, followed by increased  PUMA upregulation and decreased NF-κB activity.   
Pan et al. [21] have reported that silencing of p65/relA does not sensitize PANC-1cells to gemcitabine 
in  vitro  and  in  vivo.  We  therefore  suggest  that  gemcitabine  alone  or  in  combination  with  AKT2 
inhibition inhibits in vivo tumor growth by PUMA upregulation, but not by NF-κB downregulation in 
PANC-1established tumors. 
In  L3.6pl  cells  in  vitro,  inhibition  of  AKT2  enhances  sensitivity  to  gemcitabine,  followed  by 
decreased NF-κB activity. When the NF-κB activity was recovered, enhancement of apoptosis induced 
by  gemcitabine combined with AKT2  siRNA was  decreased significantly  when  activity of  NF-κB 
activity and its downstream bcl-2 protein was increased in  L3.6pl cells. However, PUMA did not 
undergo  obvious  changes.  These  results  indicated  that  inhibition  of  AKT2  enhanced  sensitivity  to 
gemcitabine via an NF-κB-dependent, but not the PUMA pathway in L3.6pl cells in vitro. In L3.6pl 
established tumors, gemcitabine  significantly  inhibited  tumor growth, followed by upregulation of 
PUMA  and  NF-κB.  When  rAAV2-AKT2  siRNA  combined  with  gemcitabine  treatment  inhibited 
NF-KB activity, tumor growth was not inhibited, compared with gemcitabine treatment alone. We 
therefore suggest that AKT2 inhibition did not sensitize L3.6pl cells to gemcitabine in vivo. Silencing 
of p65/relA by AKT2 inhibition did not sensitize gemcitabine to L3.6pl cells in vivo, contrary to the 
study of Pan et al. [21]. 
BxPC-3  would  have  been  sensitive  to  the  tested  agent  gemcitabine,and  gemcitabine  treatment 
increased activity of NF-κB and its downstream bcl-2 protein significantly. PUMA and its downstream 
were also increased significantly. A previous study has shown that knockdown of NF-κB sensitizes 
BxPC-3  cells  to  gemcitabine  [21].  Our  present  study  found  that  PUMA  was  also  required  for 
gemcitabine-induced  apoptosis  in  pancreatic  cancer  cell  line  BxPC-3.  We  therefore  conclude  that 
BxPC-3 cells were sensitized to gemcitabine via both an NF-κB- and PUMA-dependent pathway, but Int. J. Mol. Sci.2012, 13  1204 
 
not the AKT2/pAKT pathway  in vitro.  In  BxPC-3 established tumors, gemcitabine and combined 
treatment did not have an obvious effect on tumor growth and apoptosis, in contrast to the study of   
Pan et al. [21], however, it was consistent with the recent study by Pham et al. [60]. 
5. Conclusions 
The level of AKT activation is not likely to be useful in selecting individual pancreatic tumors for 
AKT inhibition in combination with gemcitabine. The sensitivity levels of pancreatic cancer cells to 
gemcitabine are different. AKT inhibition sensitizes pancreatic cancer cells to gemcitabine via PUMA 
upregulation and/or decreased NF-κB activity. Our findings suggest that AKT inhibitors may have 
therapeutic potential when used in combination with gemcitabine in reversing drug resistance in some 
pancreatic cancer patients. 
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